신경보호 시장 : 제품별, 투여 경로별, 용도별, 유통 채널별, 세계 예측(2024-2032년)

Global Neuroprotection Market will witness 7.1% CAGR between 2024 and 2032 due to increasing research and development in the field. Neuroprotection involves strategies aimed at preserving the structure and function of neurons in the brain and nervous system. As our understanding of neurological diseases and injuries improves, so does the need for effective neuroprotective treatments.

For instance, in October 2023, two recent studies on the potential neuroprotective agent nerinetide (NoNO Inc) for acute ischemic stroke patients revealed conflicting yet intriguing findings. Michael Hill, MD, a neurology professor at the University of Calgary, Canada, who led the ESCAPE-NEXT trial, admitted that the trial's results were disappointing. However, he expressed that the FRONTIER results were highly promising and indicated the importance of administering this agent as early as feasible.

Researchers are exploring various approaches, including pharmacological interventions, gene therapy, stem cell therapy, and neuroprotective agents. With advancements in neuroscience, there is growing optimism for the development of novel treatments to prevent or slow down the progression of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis. Consequently, there is a rising demand for neuroprotective therapies, driving growth in the neuroprotection market.

The overall Neuroprotection Industry is classified based on the product, route of administration, application, distribution channel, and region.

The apoptosis inhibitors segment will undergo notable development from 2024 to 2032. Apoptosis, or programmed cell death, plays a significant role in neurodegenerative diseases and injuries by causing the death of neurons. Apoptosis inhibitors are designed to block this process, preserving neuronal function and structure. These inhibitors hold promise in treating conditions like stroke, Alzheimer's, and Parkinson's disease. As research advances, more effective apoptosis inhibitors are being developed, driving demand in the neuroprotection market. The ability of apoptosis inhibitors to potentially slow or halt neurodegeneration makes them a focal point in the quest for novel neuroprotective therapies.

The neuroprotection market share from the intravenous segment will register a noteworthy CAGR from 2024 to 2032. Intravenous delivery offers direct and rapid access to the bloodstream, ensuring efficient distribution of neuroprotective agents to the brain and spinal cord. This route is particularly crucial in acute conditions like stroke, traumatic brain injury, and neurodegenerative diseases where immediate action is required. Additionally, intravenous administration allows for precise dosing and continuous infusion, optimizing therapeutic outcomes. As researchers develop new neuroprotective agents and formulations suitable for intravenous delivery, the demand for such treatments continues to grow, shaping the neuroprotection market landscape.

Asia Pacific neuroprotection market will showcase a commendable CAGR from 2024 to 2032. With a rapidly aging population and increasing incidence of neurological disorders, there's a pressing need for effective treatments. Countries in Asia-Pacific are investing in healthcare infrastructure and research, fostering innovation and development of neuroprotective therapies. Moreover, rising disposable incomes and awareness about neurological health are propelling demand for these treatments. Governments are implementing policies to address healthcare needs, further boosting market growth. As a result, the Asia-Pacific region is becoming a focal point for neuroprotection research and development, driving demand for neuroprotective therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurological disorders
    • 3.2.1.2 Technological advancements in drug delivery systems
    • 3.2.1.3 Aging population and demographic shifts
    • 3.2.1.4 Increasing research and development investments
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antioxidants
• 5.3 Apoptosis inhibitors
• 5.4 Anti-inflammatory agents
• 5.5 Glutamate antagonists
• 5.6 Metal ion chelators
• 5.7 Antidepressants
• 5.8 Stimulants
• 5.9 Neurotrophic factors (NTFs)
• 5.10 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Intravenous
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Neurodegenerative diseases
• 7.3 Stroke and ischemic injury
• 7.4 Traumatic brain injury (TBI)
• 7.5 Depression and bipolar disorders
• 7.6 Spinal cord injury
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Drug stores
• 8.5 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Biogen Inc.
• 10.3 Dr. Reddy's Laboratories Ltd.
• 10.4 Eli Lilly and Company
• 10.5 GSK plc
• 10.6 Merck & Co., Inc.
• 10.7 Novartis AG
• 10.8 Pfizer Inc.
• 10.9 Sanofi
• 10.10 Teva Pharmaceutical Industries Limited